3H-Ketanserin | 112307-74-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3H-Ketanserin
• 英文别名: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]-1,1,2,2-tetratritioethyl]-1H-quinazoline-2,4-dione
• CAS: 112307-74-1
• 化学式: C22H22FN3O3
• 分子量: 403.5
• InChiKey: FPCCSQOGAWCVBH-PSQIVULCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3H-Ketanserin 、 三羟甲基氨基甲烷盐酸盐 、 二甲基亚砜 反应 0.33h， 生成 5-羟基色胺
  参考文献：
  名称：

  DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS

  摘要：

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。

  公开号：

  US20120028920A1

文献信息

• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Yamashita Hiroshi

  公开号：US20090264404A1

  公开（公告）日：2009-10-22

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，其化学式为（1）：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香族基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的谱，包括中枢神经系统障碍，无副作用且安全性高。
• PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20110152286A1

  公开（公告）日：2011-06-23

  The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  本发明提供了一个由通式（1）所代表的杂环化合物：该化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Maruyama Megumi

  公开号：US20120214790A1

  公开（公告）日：2012-08-23

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar 1 and Ar 2 are aryl or heteroaryl; V is nitrogen, or CR 3 ; W 1 is a single bond, —C(O)—, etc.; W 2 is C 1 -alkylene; W 3 is a single bond, methylene, —NH—, —CR 4 ═CR 5 —, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R 1a , R 1b and R 1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C 1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍表现出高效性，并且降低了传统副作用风险，对于除精神分裂症以外的与认知功能障碍相关的中枢神经系统疾病具有显著的效果。公式（1）中的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的基团，在其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a，R1b和R1c分别相同或不同，是氢，羟基，卤素，氰基，C1-6烷基等；或其药学上可接受的盐。
• N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
  申请人：Maruyama Megumi

  公开号：US08541585B2

  公开（公告）日：2013-09-24

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, —C(O)—, etc.; W2 is C1-alkylene; W3 is a single bond, methylene, —NH—, —CR4═CR5—, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，并减少传统的副作用风险，同时对于与精神分裂症不同的认知功能相关的中枢神经系统疾病具有显著的效果。本发明提供了式（1）的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂芳基；V为氮或CR3；W1为单键，-C（O）-等；W2为C1-烷基；W3为单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的一个基团，其中n为0或1；m为0到2；k为1到3；Z为单键，亚甲基，氧等；R1a、R1b和R1c分别为相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药学上可接受的盐。
• Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US20160051548A1

  公开（公告）日：2016-02-25

  The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  本发明提供了一个由通式（1）所表示的杂环化合物。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，没有副作用且具有高安全性。